Literature DB >> 1848733

Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes.

C D Nicholson1, R A Challiss, M Shahid.   

Abstract

Since the discovery of cyclic nucleotide phosphodiesterase 30 years ago, there have been major advances in our knowledge of this group of isoenzymes. Five families, each composed of several isoforms and having differing tissue distributions, have been described. David Nicholson and colleagues compare the tissue distribution of phosphodiesterase isoenzymes and discuss the differential effects of inhibition of particular isoenzymes, with differing subcellular localization, on tissue function. They also review the potential use of isoenzyme selective phosphodiesterase inhibitors in a range of clinical disorders such as heart failure, asthma, depression and dementia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1848733     DOI: 10.1016/0165-6147(91)90484-a

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  80 in total

Review 1.  Recent advances in asthma.

Authors:  P J Barnes; T H Lee
Journal:  Postgrad Med J       Date:  1992-12       Impact factor: 2.401

2.  Vinpocetine selectively inhibits neurotransmitter release triggered by sodium channel activation.

Authors:  M Sitges; V Nekrassov
Journal:  Neurochem Res       Date:  1999-12       Impact factor: 3.996

Review 3.  Phosphodiesterase inhibitors.

Authors:  Victoria Boswell-Smith; Domenico Spina; Clive P Page
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

4.  Age-dependent changes in second messenger and rolipram receptor systems in the gerbil brain.

Authors:  T Araki; H Kato; Y Kanai; K Kogure
Journal:  J Neural Transm Gen Sect       Date:  1994

5.  Alpha 2-adrenoceptor mediated inhibition of forskolin-stimulated cyclic AMP accumulation in isolated porcine palmar lateral veins.

Authors:  I K Wright; D A Kendall; V G Wilson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-08       Impact factor: 3.000

6.  Role of cyclic AMP in promoting the thromboresistance of human endothelial cells by enhancing thrombomodulin and decreasing tissue factor activities.

Authors:  G Archipoff; A Beretz; K Bartha; C Brisson; C de la Salle; C Froget-Léon; C Klein-Soyer; J P Cazenave
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

7.  Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea-pig.

Authors:  M M Teixeira; A G Rossi; T J Williams; P G Hellewell
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

8.  Relaxation of guinea-pig trachea by cyclic AMP phosphodiesterase inhibitors and their enhancement by sodium nitroprusside.

Authors:  N C Turner; J Lamb; A Worby; K J Murray
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

9.  Cardiotonic actions of selective phosphodiesterase inhibitors in rat isolated ventricular cardiomyocytes.

Authors:  E J Kelso; B J McDermott; B Silke
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

10.  KS-505a, an isoform-selective inhibitor of calmodulin-dependent cyclic nucleotide phosphodiesterase.

Authors:  M Ichimura; R Eiki; K Osawa; S Nakanishi; H Kase
Journal:  Biochem J       Date:  1996-05-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.